Imugene (ASX:IMU) has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its patent application number that protects its oncolytic virotherapy CF33-CD19 and its combination with CD19 targeting CAR-T cell therapies. …
Latest Video
New Stories
-
Cartherics emerges as Asia Pacific leader in off the shelf immune cell therapy
July 2, 2026 - - Australian Biotech -
The minister is following a tried and tested process, but what is the risk in this new world?
July 1, 2026 - - Latest News -
Patient alarm over the potential loss of subsidised access to MS medicines
July 1, 2026 - - Latest News -
Pharmacy Guild rejects AMA alarm over broader prescribing powers
July 1, 2026 - - Latest News -
Significant day marked by negotiation trigger and wholesaler remuneration changes
July 1, 2026 - - Latest News -
Governments backs inhaled RNA therapy with the potential to change the future of chronic lung disease treatment
July 1, 2026 - -
Protection gap leaves older Australians vulnerable this winter
July 1, 2026 - - Latest News